$ATAI
ATAI Life Sciences NV

2023 Q2 Form 10-Q Financial Statement

#000095017023021271 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $172.0K $37.00K
YoY Change 1.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.56M $13.97M
YoY Change -3.85% -22.31%
% of Gross Profit
Research & Development $15.48M $19.28M
YoY Change -13.78% 24.72%
% of Gross Profit
Depreciation & Amortization $79.00K $65.00K
YoY Change 315.79% 8.33%
% of Gross Profit
Operating Expenses $32.03M $33.25M
YoY Change -9.83% -0.57%
Operating Profit -$31.86M -$33.21M
YoY Change -9.88% -0.68%
Interest Expense $658.0K $622.0K
YoY Change -86.84% -72.49%
% of Operating Profit
Other Income/Expense, Net $204.0K $58.00K
YoY Change -95.52% -96.19%
Pretax Income -$31.66M -$33.16M
YoY Change 2.77% 3.87%
Income Tax $185.0K $200.0K
% Of Pretax Income
Net Earnings -$33.04M -$33.14M
YoY Change -9.77% -10.13%
Net Earnings / Revenue -19210.47% -89554.05%
Basic Earnings Per Share -$0.21 -$0.21
Diluted Earnings Per Share -$0.21 -$0.21
COMMON SHARES
Basic Shares Outstanding 166.0M 166.0M
Diluted Shares Outstanding 155.8M 155.8M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $227.5M $249.9M
YoY Change -27.2% -25.39%
Cash & Equivalents $141.1M $185.9M
Short-Term Investments $86.40M $64.00M
Other Short-Term Assets $1.435M $1.982M
YoY Change 8.55% 42.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $242.8M $267.9M
YoY Change -24.98% -23.18%
LONG-TERM ASSETS
Property, Plant & Equipment $1.043M $1.114M
YoY Change 244.22% 525.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $5.846M
YoY Change -100.0% -40.03%
Other Assets $3.267M $3.180M
YoY Change -56.96% -57.62%
Total Long-Term Assets $10.83M $12.78M
YoY Change -57.26% -63.42%
TOTAL ASSETS
Total Short-Term Assets $242.8M $267.9M
Total Long-Term Assets $10.83M $12.78M
Total Assets $253.6M $280.7M
YoY Change -27.32% -26.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.859M $4.915M
YoY Change 40.94% 36.07%
Accrued Expenses $12.86M $13.82M
YoY Change -32.03% -24.29%
Deferred Revenue
YoY Change
Short-Term Debt $86.40M $64.00M
YoY Change -62.17% -69.65%
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $17.93M $19.95M
YoY Change -18.36% -9.68%
LONG-TERM LIABILITIES
Long-Term Debt $15.29M $15.21M
YoY Change 2369.79% 1997.24%
Other Long-Term Liabilities $2.807M $2.816M
YoY Change -28.03% -31.75%
Total Long-Term Liabilities $2.807M $2.816M
YoY Change -28.03% -31.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.93M $19.95M
Total Long-Term Liabilities $2.807M $2.816M
Total Liabilities $37.96M $40.08M
YoY Change 31.73% 36.43%
SHAREHOLDERS EQUITY
Retained Earnings -$576.9M -$543.8M
YoY Change 33.76% 37.78%
Common Stock $18.57M $18.57M
YoY Change 2.52% 3.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $212.6M $236.8M
YoY Change
Total Liabilities & Shareholders Equity $253.6M $280.7M
YoY Change -27.32% -26.85%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$33.04M -$33.14M
YoY Change -9.77% -10.13%
Depreciation, Depletion And Amortization $79.00K $65.00K
YoY Change 315.79% 8.33%
Cash From Operating Activities -$22.61M -$21.11M
YoY Change 3.11% -11.99%
INVESTING ACTIVITIES
Capital Expenditures $128.0K $280.0K
YoY Change -159.26% 400.0%
Acquisitions
YoY Change
Other Investing Activities -$21.88M $16.46M
YoY Change 21.55%
Cash From Investing Activities -$22.01M $16.02M
YoY Change 20.81% -107.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -100.0K 206.0K
YoY Change -105.57% 56.06%
NET CHANGE
Cash From Operating Activities -22.61M -21.11M
Cash From Investing Activities -22.01M 16.02M
Cash From Financing Activities -100.0K 206.0K
Net Change In Cash -44.72M -4.728M
YoY Change 16.6% -98.02%
FREE CASH FLOW
Cash From Operating Activities -$22.61M -$21.11M
Capital Expenditures $128.0K $280.0K
Free Cash Flow -$22.74M -$21.39M
YoY Change 4.73% -11.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
00000
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001840904
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40493
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ATAI Life Sciences N.V.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
ATAI Life Sciences N.V.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Wallstraße 16, 10179
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Berlin
CY2023Q1 dei Entity Address Country
EntityAddressCountry
DE
CY2023Q1 dei City Area Code
CityAreaCode
49 89
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
2153 9035
CY2023Q1 dei Security12b Title
Security12bTitle
Common shares, par value €0.10 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ATAI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
166010476
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185885000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190613000
CY2023Q1 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
63998000
CY2022Q4 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
82496000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9199000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14036000
CY2023Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
8851000
CY2022Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0
CY2023Q1 us-gaap Assets Current
AssetsCurrent
267933000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
287145000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1114000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
928000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1489000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2023Q1 us-gaap Other Long Term Investments
OtherLongTermInvestments
5846000
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
6755000
CY2023Q1 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
1155000
CY2022Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
7262000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3180000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3125000
CY2023Q1 us-gaap Assets
Assets
280717000
CY2022Q4 us-gaap Assets
Assets
305441000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4915000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2399000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13819000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17306000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
317000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
180000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
902000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19953000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19897000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
918000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
953000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1185000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2023Q1 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
422000
CY2022Q4 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
415000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
14783000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
14702000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2816000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3664000
CY2023Q1 us-gaap Liabilities
Liabilities
40077000
CY2022Q4 us-gaap Liabilities
Liabilities
39675000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166010476
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166010476
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
165935914
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
165935914
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
18571000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18562000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
782926000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
774092000
CY2023Q1 atai Share Subscription Receivable
ShareSubscriptionReceivable
0
CY2022Q4 atai Share Subscription Receivable
ShareSubscriptionReceivable
-24000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20823000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21702000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-543849000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-510188000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
236825000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260740000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
3815000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
5026000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
240640000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
265766000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
280717000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305441000
CY2023Q1 us-gaap Revenues
Revenues
37000
CY2022Q1 us-gaap Revenues
Revenues
0
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
19281000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15460000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13970000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17982000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
33251000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
33442000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33214000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33442000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
275000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
98000
CY2023Q1 us-gaap Interest Expense
InterestExpense
622000
CY2022Q1 us-gaap Interest Expense
InterestExpense
0
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-35000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2023Q1 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
964000
CY2022Q1 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
-740000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-837000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2163000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
243000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
58000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1521000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33156000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31921000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
165000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1033000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5596000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34354000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1219000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-689000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33135000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36869000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155792490
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155792490
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153529268
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153529268
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34354000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
879000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4373000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33475000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-41931000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1219000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
689000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
8000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-11000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1211000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-700000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32264000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41231000
CY2022Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
265766000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
181000
CY2023Q1 atai Settlement Of Issuance Of Common Shares Value
SettlementOfIssuanceOfCommonSharesValue
24000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8662000
CY2023Q1 atai Adjustment To Accumulated Deficit Pursuant To Adoption Of Asu201613
AdjustmentToAccumulatedDeficitPursuantToAdoptionOfAsu201613
-526000
CY2023Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
887000
CY2023Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-34354000
CY2023Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
240640000
CY2021Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
385959000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
132000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10208000
CY2022Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-4384000
CY2022Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-37558000
CY2022Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
354357000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34354000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
65000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
CY2023Q1 atai Change In Right Of Use Asset
ChangeInRightOfUseAsset
102000
CY2022Q1 atai Change In Right Of Use Asset
ChangeInRightOfUseAsset
0
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
82000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-35000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2023Q1 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
964000
CY2022Q1 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
-740000
CY2023Q1 atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
1033000
CY2022Q1 atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
5596000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8662000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10208000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-832000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1519000
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-194000
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-60000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4873000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1289000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2476000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1886000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3689000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1722000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21111000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23986000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
280000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000
CY2023Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
163000
CY2022Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
0
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
211680000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19461000
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0
CY2023Q1 us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
CY2022Q1 us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16018000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214736000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
206000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
132000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
206000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
299000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4728000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-238291000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190613000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362266000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
185885000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123975000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
452000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023Q1 atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
CY2022Q1 atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
245000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="footnotes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Or</span><span id="notes"/><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">atai was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. atai did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In contemplation of the consummation of atai’s initial public offering (“IPO”) of common shares, atai undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. In June 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, atai closed the IPO of its common shares on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common shares, which included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has continued to present global public health and economic challenges during the three months ended March 31, 2023. Although some research and development timelines have been impacted by delays related to the COVID-19 pandemic, the Company has not experienced material financial impacts on its business and operations as a result. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">543.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company has historically financed its operations through the sale of equity securities, debt financings, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of March 31, 2023 will be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the condensed consolidated financial statements are issued.</span></p>
CY2023Q1 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1 to 10 basis
CY2021Q2 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1.6 to one
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185900000
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
64000000.0
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-543800000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
8351000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), securities carried at fair value, contingent consideration liability—related parties, in-process research and development assets (“IPRD”) and noncontrolling interests recognized in acquisitions, the valuation of share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
146795000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
154830000
CY2023Q1 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0
CY2022Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0
CY2023Q1 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
5800000
CY2023Q1 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
8900000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
100000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain reclassifications were made to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform with current year presentation due to the increase in the balances of the Company's operating right-of-use asset and related lease liability during the period.</span></p>
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2200000
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1000000.0
CY2022Q4 us-gaap Minority Interest
MinorityInterest
5026000
CY2023Q1 atai Net Loss Attributable To Redeemable Noncontrolling Interests Common
NetLossAttributableToRedeemableNoncontrollingInterestsCommon
0
CY2023Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-1219000
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-8000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
3815000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
9051000
CY2022Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-689000
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-11000
CY2022Q4 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
6800000
CY2022Q4 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
7200000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q1 us-gaap Other Long Term Investments
OtherLongTermInvestments
5846000
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
6755000
CY2023Q1 atai Equity Method Investment Shares Transaction Date
EquityMethodInvestmentSharesTransactionDate
2026-12-31
CY2023Q1 us-gaap Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions
9600000
CY2023Q1 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2300000
CY2022 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2400000
CY2023Q1 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0
CY2021Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3000000.0
CY2023Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
200000
CY2023Q1 us-gaap Loans And Leases Receivable Net Reported Amount
LoansAndLeasesReceivableNetReportedAmount
9200000
CY2022Q4 us-gaap Loans And Leases Receivable Net Reported Amount
LoansAndLeasesReceivableNetReportedAmount
5500000
CY2023Q1 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2022Q4 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2023Q1 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.050
CY2022Q4 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.050
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
980000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2034000
CY2023Q1 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
4642000
CY2022Q4 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
4626000
CY2023Q1 us-gaap Prepaid Taxes
PrepaidTaxes
1595000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
5631000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1982000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1745000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9199000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14036000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2993000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3566000
CY2023Q1 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
5323000
CY2022Q4 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
5550000
CY2023Q1 atai Accrued Restructuring Costs
AccruedRestructuringCosts
708000
CY2022Q4 atai Accrued Restructuring Costs
AccruedRestructuringCosts
0
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2118000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5260000
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
1882000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2224000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
795000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
706000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13819000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17306000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.124
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1489000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
317000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
180000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1185000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
359000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
412000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
367000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
367000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
367000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Receivable Thereafter
OperatingLeasesFutureMinimumPaymentsReceivableThereafter
122000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
1994000
CY2023Q1 us-gaap Receivable With Imputed Interest Discount
ReceivableWithImputedInterestDiscount
492000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1502000
CY2023Q1 atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
76000
CY2022Q1 atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
46000
CY2023Q1 atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
CY2022Q1 atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
245000
CY2023Q1 us-gaap Convertible Debt
ConvertibleDebt
422000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
415000
CY2023Q1 us-gaap Loans Held For Sale Maturity Date
LoansHeldForSaleMaturityDate
2026-08-01
CY2023Q1 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
175000000.0
CY2023Q1 atai Prime Rate Percent
PrimeRatePercent
0.0455
CY2023Q1 atai Accrued Interest Payable
AccruedInterestPayable
0.0855
CY2022Q3 atai Borrowing Amount Percentage
BorrowingAmountPercentage
0.33
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2023Q1 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2022Q4 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-258000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-274000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-106000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-113000
CY2023Q1 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-895000
CY2022Q4 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-952000
CY2023Q1 us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet
14783000
CY2022Q4 us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet
14702000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
14783000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
14702000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7300000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34354000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1219000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-689000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33135000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33135000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36869000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-36869000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155792490
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155792490
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153529268
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153529268
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58608879
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50168788
CY2023Q1 atai Related Party Reservation Rate Of Common Shares For Ipo
RelatedPartyReservationRateOfCommonSharesForIpo
0.27
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
200000
CY2023Q1 atai Percentage Of Restructed Workforce
PercentageOfRestructedWorkforce
0.30
CY2023Q1 us-gaap Restructuring Costs
RestructuringCosts
3200000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
700000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q1 us-gaap Restructuring Costs
RestructuringCosts
3166000
CY2023Q1 atai Non Cash Impact Of Stock Based Compensation
NonCashImpactOfStockBasedCompensation
195000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
2263000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
708000

Files In Submission

Name View Source Status
atai-20230331_lab.xml Edgar Link unprocessable
atai-20230331_cal.xml Edgar Link unprocessable
atai-20230331_def.xml Edgar Link unprocessable
0000950170-23-021271-index-headers.html Edgar Link pending
0000950170-23-021271-index.html Edgar Link pending
0000950170-23-021271.txt Edgar Link pending
0000950170-23-021271-xbrl.zip Edgar Link pending
atai-20230331.htm Edgar Link pending
atai-20230331.xsd Edgar Link pending
atai-20230331_htm.xml Edgar Link completed
atai-ex31_1.htm Edgar Link pending
atai-ex31_2.htm Edgar Link pending
atai-ex32_1.htm Edgar Link pending
atai-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img105938706_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
atai-20230331_pre.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending